Lyra Therapeutics, Inc. (LYRA) Financials
LYRA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 120.6 million | 36.3 million |
2023-06-30 | 125.7 million | 27.1 million |
2023-03-31 | 93.9 million | 27.8 million |
2022-12-31 | 110.0 million | 29.2 million |
LYRA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -14.3 million | 1.4 million |
2023-06-30 | -14.4 million | 1.4 million |
2023-03-31 | -15.9 million | 1.6 million |
2022-12-31 | -12.2 million | 1.8 million |
LYRA Net Income
No data available :(
LYRA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 102.6 million | - | 6.3 million |
2023-06-30 | 116.2 million | - | 1.7 million |
2023-03-31 | 82.7 million | - | 2.1 million |
2022-12-31 | 97.9 million | - | 2.2 million |
LYRA Shares Outstanding
LYRA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 144000 | 12.4 million | 5.0 million | - |
2023-06-30 | 71000 | 10.8 million | 4.6 million | - |
2023-03-31 | 45000 | 12.6 million | 5.1 million | - |
2022-12-31 | 28000 | 9.5 million | 4.4 million | - |
LYRA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 544000 | 12.4 million |
2023-06-30 | 458000 | 10.8 million |
2023-03-31 | 410000 | 284000 |
2022-12-31 | 11000 | 222000 |
LYRA
Price: $4.03
52 week price:
Earnings Per Share: -1.26 USD
P/E Ratio: -3.34
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 10913
Market Capitalization: 299.9 million